Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Long-term hormone therapy may increase cataract risk in women with T2D

23 Mar 2020

Use of hormone therapy in the long term potentially carries a heightened risk of cataract in postmenopausal women with type 2 diabetes (T2D), a study reports.

Researchers examined whether postmenopausal hormone therapy use interacted with diabetes, which is a known risk factor for several age-related eye diseases. They used data from the Canadian Longitudinal Study on Aging and included 15,320 community-dwelling women aged 45–85 years.

All participants completed questionnaires to report menopausal status and hormone therapy use, as well as physician diagnosis of diabetes or eye disease. Multivariable logistic regression was applied.

In an analysis controlled for demographic, lifestyle and health variables, a multiplicative interaction was observed between HT use and T2D in their relationship with cataract. Specifically, exposure to HT for 10 years conferred much greater odds of having cataract in women with T2D (odds ratio [OR], 2.44, 95 percent confidence interval [CI], 1.49–3.99; p-interaction=0.013).

The increased cataract risk was not seen in long-term HT users with no diabetes (OR, 1.03, 95 percent CI, 0.87–1.21). Moreover, HT use showed no association with glaucoma or macular degeneration.

According to researchers, additional studies are needed to confirm the current findings. If confirmed, physicians should inform women with T2D about the elevated risk of cataract associated with long-term HT use.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.